A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma

Even though the prognosis of patients with multiple myeloma is continuing to improve, all patients eventually develop relapsed refractory disease. Several novel therapeutics have been developed in the last few years including the second-generation proteasome inhibitor carfilzomib which has been appr...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Therapeutic Advances in Hematology 2016-12, Vol.7 (6), p.330-344
Hauptverfasser:	Franken, B., van de Donk, N.W.C.J., Cloos, J.C., Zweegman, S., Lokhorst, H.M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Inhibitor drugs Multiple myeloma Reviews
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!